Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11251 - 11275 of 11360 in total
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Matched Description: … H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551]. …
Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein . It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults...
Investigational
Matched Description: … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine …
Investigational
Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits...
Investigational
GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.
Investigational
Investigational
Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant....
Investigational
Matched Description: … In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further …
GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture systems and animal models. Study of this drug shows the...
Investigational
Matched Description: … GRN163L is a novel anti-cancer drug. …
Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. GM-CSF stimulates proliferation, activation and differentiation of...
Investigational
Matched Description: … Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and …
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
Investigational
UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. Plasmepsins are aspartyl proteases produced by the malaria parasite Plasmodium falciparum, and PMX is considered to be essential for parasite egress and invasion. UCB7362 is estimated to achieve a significant reduction in asexual blood-stage...
Investigational
Matched Description: … [A254232] UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites. …
Investigational
Remikiren is an orally active, high specificity renin inhibitor.
Experimental
NS3728 is an orally active chloride channel blocker for the treatment of cancer.
Investigational
LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders. LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. LX1031 is designed to act locally in the gastrointestinal tract by...
Investigational
Matched Description: … LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key …
Telcagepant has been investigated for the treatment of Migraine. It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine. CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the...
Investigational
Matched Description: … It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide …
Famprofazone is a nonsteroidal anti-inflammatory agent found in combination products such as ‘Gewodin’ which is marketed in Taiwan. It is important to note that the drug is metabolized to methamphetamine and amphetamine in the body and can lead to positive tests results for illicit drug use.[A236369,L34724] Famprofazone is included in...
Experimental
Matched Description: … Famprofazone is a nonsteroidal anti-inflammatory agent found in combination products such as ‘Gewodin …
Investigational
Investigational
Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
Investigational
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
ETC-588, or LUV (large unilamellar vesicles), is made of naturally occurring lipids that circulate through arteries to facilitate the role of high-density lipoprotein (HDL) in removing accumulated cholesterol and other lipids from cells including those in the arterial wall. LUV are capable of transporting excess cholesterol from the vasculature to...
Investigational
Matched Description: … Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. …
Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
Investigational
Mirfentanil is a derivative of fentanyl that presents high selectivity for the mu opioid receptor. At lower doses, it antagonizes the analgesic effects of alfentanil and substitutes for naloxone in morphine-treated monkeys; however, it also reverses naloxone-precipitated withdrawal in pigeons trained to discriminate morphine from naloxone. At high doses, it...
Experimental
Matched Description: … Mirfentanil is a derivative of fentanyl that presents high selectivity for the mu opioid receptor. …
Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Investigational
Displaying drugs 11251 - 11275 of 11360 in total